Astellas Pharma Inc.’s subsidiaries Astellas Institute for Regenerative Medicine (AIRM) and Universal Cells Inc. have entered into a research collaboration with Osaka University to develop a pluripotent stem cell-derived cartilage organoid cell therapy for the treatment of intervertebral disc degenerative disease.

Synaptogenix Inc. has entered into a new collaboration agreement with LSU Health New Orleans’ Neuroscience Center of Excellence for preclinical testing of the company’s polyunsaturated fatty acid (PUFA) analogues.

The CMT Research Foundation has formed a strategic partnership with Revir Therapeutics Inc. to advance small-molecule therapeutics that modulate the expression of the gene that causes Charcot-Marie-Tooth disease type 1A (CMT1A).

Oblique Therapeutics AB has entered into an agreement with the KTH Royal Institute of Technology to utilize KTH’s supercomputer resources for analyzing protein structures.

Italfarmaco SpA and Iktos SA have entered into a collaboration to develop next-generation histone deacetylase (HDAC) inhibitors for a variety of non-oncological diseases, including diseases affecting the central nervous system.

Revir Therapeutics Inc. has announced the achievement of a milestone under its ongoing collaboration with Asieris Pharmaceuticals Co. Ltd. to develop treatments for cancers using a novel target.

Alivexis Inc. has entered into a research collaboration agreement with Astellas Pharma Inc. to identify small-molecule compounds for a new drug target selected by Astellas.

Sibylla Biotech SpA and the University of Texas MD Anderson Cancer Center have signed a strategic collaboration agreement to discover and develop novel small molecule folding interfering degraders (FIDs) for the treatment of cancer.